Premium
In situ detection of CD73+ CD90+ CD105+ lineage: Mesenchymal stromal cells in human placenta and bone marrow specimens by chipcytometry
Author(s) -
Consentius Christine,
Mirenska Anja,
Jurisch Anke,
Reinke Simon,
Scharm Markus,
Zenclussen Ana Claudia,
Hennig Christian,
Volk HansDieter
Publication year - 2018
Publication title -
cytometry part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.316
H-Index - 90
eISSN - 1552-4930
pISSN - 1552-4922
DOI - 10.1002/cyto.a.23509
Subject(s) - cd90 , mesenchymal stem cell , bone marrow , stromal cell , cd34 , biology , pathology , cd146 , microbiology and biotechnology , immunology , medicine , stem cell
Mesenchymal stromal cells (MSCs) support endogenous regeneration and present therefore promising opportunities for in situ tissue engineering. They can be isolated and expanded from various tissues, for example, bone marrow, adipose tissue, or placenta. The minimal consensus definition criteria of ex vivo expanded MSCs requires them to be positive for CD73, CD90, and CD105 expression, while being negative for CD34, CD45, CD14, CD19, and HLA‐DR. This study aimed to compare the in situ phenotype of MSCs with that of their culture‐expanded progeny. We report for the first time in situ detection of cells expressing this marker combination in human placenta cryosections as well as in bone marrow aspirates using multiplex‐immunohistology (Chipcytometry), a technique that allows staining of more than 100 biomarkers consecutively on the same cell. © 2018 International Society for Advancement of Cytometry